Explore the Agenda

7:30 am Check-In & Coffee

8:20 am Chair’s Opening Remarks

A Booming Radiopharmaceutical Landscape: Evaluating the Progress of TRPs in Europe & Beyond

8:30 am Radioligand Therapy: Successes & Future Challenges

Senior Principal Scientist & Group leader - Radioligand Therapy Drug Discovery, Novartis AG

Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.

  • Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
  • The success of Pluvicto in improving progression-free survival compared to standard care
  • New challenges and opportunities in RLT: new targets, combinations

9:00 am An Update on ProstACT Global: Comparing Standard of Care With or Without 177Lu-DOTA-Rosopatamab

Senior Director - Medical, Telix Pharmaceuticals
  • Evaluating the impact of adding 177Lu-DOTA-Rosopatamab to standard care in PSMA-positive mCRPC
  • Assessing the safety and effectiveness of 177Lu-DOTA-Rosopatamab with androgen inhibitors or taxanes
  • Exploring new therapeutic strategies for advanced prostate cancer using 177Lu-DOTA-Rosopatamab

9:30 am Delivering on the Promise of Targeted Radiopharmaceuticals: Emerging Therapy & Innovation Platforms

Chief Executive Officer, Perspective Therapeutics
  • Developing first-in-class versus best-in-class radiopharmaceuticals
  • Emerging clinical data from best-in-class approaches
  • Validation of preclinical platforms to deliver blockbuster after blockbuster

10:00 am Morning Break & Speed Networking

Discovery & Preclinical Track

Discovery & Preclinical Track

Lab Head, Molecular Imaging & RLT, Novartis AG

Chair: Josefine Reber, Lab Head, Molecular Imaging & RLT Novartis

Radioisotope Selection: Exploring Alpha VS Beta Emitters

11:00 am Elucidating Radiobiological Mechanisms of Cytotoxicity & Immune Modulation to Inform Selection of Optimal Radiopharmaceutical Targets

Director - Oncology Safety Sciences, AstraZeneca
  • Investigating the cellular and molecular mechanisms underlying radiopharmaceutical-induced cell death to optimise therapeutic outcomes
  • Exploring how radiopharmaceuticals interact with the immune system to enhance anti-tumour immunity and reduce resistance
  • Leveraging insights from radiobiology and immune modulation to identify and select optimal radiopharmaceutical targets for improved tumour control and reduced toxicity

11:30 am Session Reserved for BIOEMTECH

12:00 pm Strategies for Targeted Isotope Delivery to Tumours

Vice President, Research, Y-mAbs Therapeutics Inc
  • Exploring how different targeting strategies enhance selective isotope delivery to tumour sites
  • Identifying key factors (e.g., half-life, energy emission, tissue penetration) for choosing the most effective isotopes for tumour treatment
  • Assessing how optimal isotope selection improves tumour targeting, minimises off-target effects, and enhances therapeutic efficacy
Translational & Clinical Development Track
CMC & Sourcing Track

12:30 pm Lunch

Discovery & Preclinical Track

Exploring Targets Beyond PSMA: Ongoing Discovery to Find Real Hits on Novel Targets

1:30 pm Characterising Key Attributes of an Ideal Radiopharmaceutical Target for Alignment with Radiotherapeutic Properties

Chief Executive Officer & Chief Marketing Officer, Coretag
  • Evaluating receptor expression profiles and proximity to radiosensitive tissues
  • Defining target selection criteria based on emission characteristics of alpha versus. beta emitters
  • Exploring strategies for stromal and internalising target engagement, including FAP-directed approaches

2:00 pm Session Reserved for Navigo Proteins

2:10 pm Towards Optimising Tumour Retention of FAP-Targeting Theranostics

CEO, ActiThera
  • Discussing the promise of FAP as a target for the imaging and therapy of various solid tumours
  • Summarising approaches used in the FAP field to optimise tumour AUC
  • Exploring insights into Actithera’s approaches and molecules
Translational & Clinical Development Track
CMC & Sourcing Track

2:40 pm Afternoon Break & Poster Presentation Session

Investigating a Well-Rounded Approach to Isotope Selection from Discovery to Manufacturing

3:30 pm Lutetium 177 VS Terbium 161 – What are the Potentials for Next-Gen Radioisotopes?

CEO, Starget Pharma
  • Evaluating the differences in emission profiles, half-lives, and tissue penetration between 177Lu and 161Tb
  • Assessing the potential of 161Tb to enhance tumour cell kill through higher linear energy transfer and Auger electron emission
  • Discussing production, labelling, and regulatory considerations for integrating 161Tb into next-generation radiopharmaceuticals

4:00 pm Optimising Isotope Selection for Scalable Radiopharmaceutical Commercialisation

Head of CMC & Radiopharmaceutical Development, Ariceum Therapeutics
  • Evaluating isotope availability, production capacity, and logistics for reliable clinical and commercial use
  • Aligning isotope half-life, emission type, and energy with therapeutic goals and pharmacokinetics
  • Addressing regulatory, technical, and cost considerations for efficient scale-up and market readiness

4:30 pm Exploring Strategies for Improved Global Radio-Isotope & Therapy Supply Chain Management

Head of External Supply Management Radiopharmaceuticals, Bayer
  • Investigating current challenges and solutions in global actinium-225 production and distribution
  • Emerging technologies and infrastructure for scalable, high-purity isotope generation
  • Addressing regulatory, logistical, and economic barriers to support widespread adoption of actinium-based therapies

5:00 pm Chairs Closing Remarks

5:10 pm End of Scientific Programme Day One